代谢综合征
医学
心钠素
内科学
利钠肽
胰岛素抵抗
NPR1
血压
2尼泊尔卢比
心脏病学
安慰剂
内分泌学
糖尿病
不利影响
药理学
胰岛素
心力衰竭
病理
替代医学
作者
Xiao Ma,Paul M. McKie,Seethalakshmi Iyer,Christopher Scott,Kent R. Bailey,Brynte H. Johnson,Sherry L. Benike,Horng H. Chen,Wayne L. Miller,Aderville Cabassi,John C. Burnett,Valentina Cannone
标识
DOI:10.1016/j.jacbts.2023.08.011
摘要
Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome. M-atrial natriuretic peptide is a novel atrial natriuretic peptide analog that activates the particulate guanylyl cyclase A receptor. This study conducted a double-blind, placebo-controlled trial in 22 patients and demonstrated that a single subcutaneous injection of M-atrial natriuretic peptide was safe, well-tolerated, and exerted pleiotropic properties including blood pressure–lowering, lipolytic, and insulin resistance–improving effects. (MANP in Hypertension and Metabolic Syndrome [MANP-HTN-MS]; NCT03781739)
科研通智能强力驱动
Strongly Powered by AbleSci AI